The role of genomic tests in personalised medicine for colon cancer

Phase 1-2 results for oral proteasome inhibitor MLN9708 for multiple myeloma (Spanish)

BRCA carrier status as a prognostic factor for prostate cancer

Retrospective study of optimal treatment for intermediate-risk testes cancer

Combined chemo-radiation extends survival for anaplastic oligodendroglial tumours

Effects of age on treatment and outcomes in women with stage IB-IIB cervical cancer

Insight in to the EMILIA trial and systemic challenges with neoadjuvant therapy

MEK inhibitor, trametinib, improves progression free survival in melanoma

SUCCEED trial: Maintenance treatment in advance soft tissue sarcoma

Drug development in small cell and non-small cell lung cancer

ASCO 2012 Drug Development Research Professorship

Early phase trial of ibrutinib for chronic lymphocytic leukaemia

Novel PET tracers and their future use in assessment of response to treatment

Treating metastatic melanoma with vemurafenib

Clinical trials for rare tumour types

Role of family history and genetic testing in diagnosis

First line treatment against metastatic breast cancer

Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma

Effects of panitumumab against oesophageal-gastro cancer and carcinomas

Effects of lapatinib and trastuzumab on progression free survival

Decision making in surgical breast cancer treatment

Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

ASCO 2012: Advances in myeloma

ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma

President's overview of ASCO 2012

Drug shortage impact on cancer care and efforts to resolve the issue

Patient perspective on drug shortages

Recommendations for averting drug shortages

FDA's comments on drug shortages

New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma

New MEK inhibitor, trametinib, improves survival in advanced melanoma

Increased risk of breast cancer among young women treated with radiation as a child

First effective treatment for chemotherapy-induced peripheral neuropathy

Afatinib delays progression of advanced lung adenocarcinomas

Costly drugs versus paclitaxel as first line therapy for locally advanced or metastatic breast cancer

Routine molecular testing of non-small cell lung cancers in community settings

Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

Better taking of family histories and referral to genetic counselling

EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2-positive breast cancer

Increased progression-free survival in advanced lung cancer with afatinib

Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer

Changing the standard treatment for lymphoma with bendamustine

Trastuzumab emtansine improves progression-free survival for HER2-positive breast cancer

Continuing bevacizumab with second-line chemotherapy for colorectal cancer

Combined chemo-radiation extends survival in patients with anaplastic oligodendroglial tumours

Intermittent hormonal therapy less effective than continuous therapy when treating advanced prostate cancer

Lower-income Patients are less likely to participate in clinical trials

Bendamustine regimen more effective for lymphoma than standard CHOP

Early results from new PD-1 targeted immune therapy

New study asks patients preference on kidney cancer treatment

Relapse and survival of adolescent and young adult leukaemia patients

Adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer improves progression-free survival